Navigation Links
Neurobiological Technologies' CEO to Retire on December 31, 2008
Date:7/7/2008

EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. Mr. Freiman is the former chief executive officer of Syntex Corporation of Palo Alto, California.

Mr. Freiman is retiring after 11 years of service to the company. "Paul's strong leadership has helped grow our company to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our organization will be long- lasting. We thank him for his dedicated service and wish him the best as he moves on to the next chapter in his life," said Abraham E. Cohen, NTI's chairman of the Board of Directors.

Mr. Freiman stated, "Since I stepped into the role of an interim CEO in 1997, I have enjoyed all aspects of my time at NTI. I remain committed to our principal product, Viprinex(TM), which may provide an extraordinary opportunity in the treatment of acute ischemic stroke. I have announced my intent so that the Board of Directors has sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active NTI director beyond my retirement."

A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva North America, to search for a new CEO and has engaged the services of a retained search firm.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Neurobiological Technologies Sets Date for Third Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Sets Date for Research and Development Day
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
9. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
10. Neurobiological Technologies Sets Date for Second Quarter Financial Results
11. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ... July 13, 2017 , ... Thousands of pilots from across ... the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete in various categories ... on US teams that participate in world championships. , RC Pylon (July 14-21): One ...
(Date:7/13/2017)... ... 13, 2017 , ... Frederick’s first and only science and ... the past year after an intensive restructuring. Under the leadership of CEO Kathie ... its board of directors to revitalize the organization. As a result, FITCI is ...
(Date:7/12/2017)... ... 12, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a ... for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of ... offering will be $7,071,192. , The shares will begin trading on July 12, 2017 ...
(Date:7/12/2017)... ... July 12, 2017 , ... Exact Diagnostics continues to ensure consistent results by ... use. Panels available include: Adenovirus, BKV, CMV, EBV, HBV, HCV, HHV-6A, ... Verification Panels may be used as calibrators to establish reference points for the measurement ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):